Fereidoun Azizi1, Ramin Malboosbaf1. 1. Endocrine Research Center of Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences , Tehran, I.R. Iran .
Abstract
BACKGROUND: Several studies have reported inconsistent findings on the advantages and disadvantages of long-term treatment with antithyroid drugs (ATD). A systematic review and meta-analysis was undertaken to clarify the numerous aspects of long-term treatment with ATD. METHODS: Medline and the Cochrane Library for trials published between 1950 and May 2016 were systematically searched. Studies containing data for long-term (>24 months) ATD treatment were included. Summary estimates of pooled prevalence, odds ratio, and weighted mean difference were calculated with a random effects model. RESULTS: Of 587 related articles found, six fulfilled the inclusion criteria. Long-term ATD treatment induced a remission rate of 57% [confidence interval (CI) 45-68%], a rate that was higher in adults than in non-adults (61% vs. 53%). The rate of complications was 19.1% [CI 9.6-30.9%], of which only 1.5% were major complications. The annual remission rate for each year of treatment was 16% [CI 10-27%], which was higher in adults than non-adults (19% vs. 14%). However, it should be noted that this is not a true linear correlation, but a positive relationship can be suggested between time and remission rate. Meta-regression revealed that smoking had a significant lowering effect on remission rate. CONCLUSIONS: Long-term ATD treatment is effective and safe, especially in adults, indicating that it should be considered as an alternative treatment for Graves' disease.
BACKGROUND: Several studies have reported inconsistent findings on the advantages and disadvantages of long-term treatment with antithyroid drugs (ATD). A systematic review and meta-analysis was undertaken to clarify the numerous aspects of long-term treatment with ATD. METHODS: Medline and the Cochrane Library for trials published between 1950 and May 2016 were systematically searched. Studies containing data for long-term (>24 months) ATD treatment were included. Summary estimates of pooled prevalence, odds ratio, and weighted mean difference were calculated with a random effects model. RESULTS: Of 587 related articles found, six fulfilled the inclusion criteria. Long-term ATD treatment induced a remission rate of 57% [confidence interval (CI) 45-68%], a rate that was higher in adults than in non-adults (61% vs. 53%). The rate of complications was 19.1% [CI 9.6-30.9%], of which only 1.5% were major complications. The annual remission rate for each year of treatment was 16% [CI 10-27%], which was higher in adults than non-adults (19% vs. 14%). However, it should be noted that this is not a true linear correlation, but a positive relationship can be suggested between time and remission rate. Meta-regression revealed that smoking had a significant lowering effect on remission rate. CONCLUSIONS: Long-term ATD treatment is effective and safe, especially in adults, indicating that it should be considered as an alternative treatment for Graves' disease.
Authors: So Young Park; Bo Hyun Kim; Mijin Kim; A Ram Hong; Jun Park; Hyunju Park; Min Sun Choi; Tae Hyuk Kim; Sun Wook Kim; Ho-Cheol Kang; Jae Hoon Chung Journal: Endocrine Date: 2021-04-15 Impact factor: 3.633
Authors: Ari Song; Su Jin Kim; Min-Sun Kim; Jiyeon Kim; Insung Kim; Ga Young Bae; Eunseop Seo; Young Seok Cho; Joon Young Choi; Sung Yoon Cho; Dong-Kyu Jin Journal: Front Endocrinol (Lausanne) Date: 2021-06-14 Impact factor: 5.555
Authors: Eyun Song; Mina Kim; Sojeong Park; Min Jeong Park; Jung A Kim; Eun Roh; Ji Hee Yu; Nam Hoon Kim; Ji A Seo; Sin Gon Kim; Nan Hee Kim; Kyung Mook Choi; Sei Hyun Baik; Hye Jin Yoo Journal: Front Endocrinol (Lausanne) Date: 2021-10-08 Impact factor: 5.555